John R Su1, Penina Haber2, Carmen S Ng2, Paige L Marquez2, Graça M Dores3, Silvia Perez-Vilar3, Maria V Cano2. 1. Immunization Safety Office, Division of Healthcare Quality Promotion, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA, United States. Electronic address: ezu2@cdc.gov. 2. Immunization Safety Office, Division of Healthcare Quality Promotion, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA, United States. 3. Office of Biostatistics and Epidemiology, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, United States.
Abstract
BACKGROUND: Since the last review of vaccine safety surveillance data for erythema multiforme (EM), Stevens Johnson syndrome (SJS), SJS/TEN, and toxic epidermal necrolysis (TEN) (EM/SJS/TEN), over 37 new vaccines have been introduced in the United States. We sought to describe reported EM/SJS/TEN after vaccines during 1999-2017. METHODS: We identified U.S. reports of EM/SJS/TEN received by the Vaccine Adverse Event Reporting System (VAERS) during 1999-2017. We stratified analysis by condition (EM, SJS, or TEN), and analyzed reports by serious or non-serious status, sex, age group, time from vaccination to symptom onset, exposure to known causes of EM/SJS/TEN, and vaccines administered. We used Empirical Bayesian data mining to detect vaccine-AE pairs reported more frequently than expected. RESULTS: Of 466,027 reports to VAERS during 1999-2017, we identified 984 reports of EM, 89 reports of SJS, 6 reports of SJS/TEN, and 7 reports of TEN. Few reports of EM (9%), and most reports of SJS (52%), SJS/TEN (100%), and TEN (100%) were serious. Overall, 55% of reports described males, 48% described children aged < 4 years; 58% of EM/SJS/TEN occurred ≤ 7 days after vaccination. Few reports (≤5%) described exposure to known causes of EM/SJS/TEN. Overall, childhood vaccines (e.g., combined measles, mumps, and rubella vaccine) were most commonly reported. We identified 6 deaths; 4 were exposed to medications associated with EM/SJS/TEN. EM after smallpox vaccine was reported disproportionately among people aged 19-49 years. CONCLUSIONS: EM/SJS/TEN were rarely reported after vaccination; data mining identified a known association between EM and smallpox vaccine. Published by Elsevier Ltd.
BACKGROUND: Since the last review of vaccine safety surveillance data for erythema multiforme (EM), Stevens Johnson syndrome (SJS), SJS/TEN, and toxic epidermal necrolysis (TEN) (EM/SJS/TEN), over 37 new vaccines have been introduced in the United States. We sought to describe reported EM/SJS/TEN after vaccines during 1999-2017. METHODS: We identified U.S. reports of EM/SJS/TEN received by the Vaccine Adverse Event Reporting System (VAERS) during 1999-2017. We stratified analysis by condition (EM, SJS, or TEN), and analyzed reports by serious or non-serious status, sex, age group, time from vaccination to symptom onset, exposure to known causes of EM/SJS/TEN, and vaccines administered. We used Empirical Bayesian data mining to detect vaccine-AE pairs reported more frequently than expected. RESULTS: Of 466,027 reports to VAERS during 1999-2017, we identified 984 reports of EM, 89 reports of SJS, 6 reports of SJS/TEN, and 7 reports of TEN. Few reports of EM (9%), and most reports of SJS (52%), SJS/TEN (100%), and TEN (100%) were serious. Overall, 55% of reports described males, 48% described children aged < 4 years; 58% of EM/SJS/TEN occurred ≤ 7 days after vaccination. Few reports (≤5%) described exposure to known causes of EM/SJS/TEN. Overall, childhood vaccines (e.g., combined measles, mumps, and rubella vaccine) were most commonly reported. We identified 6 deaths; 4 were exposed to medications associated with EM/SJS/TEN. EM after smallpox vaccine was reported disproportionately among people aged 19-49 years. CONCLUSIONS:EM/SJS/TEN were rarely reported after vaccination; data mining identified a known association between EM and smallpox vaccine. Published by Elsevier Ltd.
Entities:
Keywords:
Data mining; Erythema multiforme; Stevens Johnson syndrome; Surveillance; Toxic epidermal necrolysis; VAERS; Vaccine; Vaccine safety
Authors: Frederick Varricchio; John Iskander; Frank Destefano; Robert Ball; Robert Pless; M Miles Braun; Robert T Chen Journal: Pediatr Infect Dis J Date: 2004-04 Impact factor: 2.129
Authors: Matthew F Daley; W Katherine Yih; Jason M Glanz; Simon J Hambidge; Komal J Narwaney; Ruihua Yin; Lingling Li; Jennifer C Nelson; James D Nordin; Nicola P Klein; Steven J Jacobsen; Eric Weintraub Journal: Vaccine Date: 2014-03-31 Impact factor: 3.641
Authors: Elif Karatas; Ali Nazim; Parth Patel; Toral Vaidya; George Scott Drew; Sanober A Amin; Ashley A Keyes; Maira Fonseca; Adnan Mir; Caroline P Halverstam Journal: JAAD Case Rep Date: 2022-01-07
Authors: Joyce Kong; Francisco Cuevas-Castillo; Mahmoud Nassar; Chi M Lei; Zarwa Idrees; William C Fix; Caroline Halverstam; Adnan Mir; Amira Elbendary; Alwin Mathew Journal: J Infect Public Health Date: 2021-07-08 Impact factor: 3.718